GRFSGrifols, S.A.

8.000USDMkt Cap: 5.44B $P/E: 10.39

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates thr…

Key Statistics

Company
Market Cap5.44B $
Enterprise Value22.13B $
Revenue (TTM)7.42B $
Gross Profit2.86B $
Net Income (TTM)402.00M $
Revenue/Share5.424 USD
Last Price8.000 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees25.3K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN
Valuation
P/E (Trailing)10.39
P/E (Forward)5.61
PEG0.19
EV/EBITDA13.45
EV/Revenue2.98
P/S0.73
P/B1.68
EPS (TTM)0.76
EPS (Forward)1.43
52W Range
7.98014% of range8.118
52W High8.118 USD
52W Low7.980 USD
Profitability
Gross Margin38.00%
Oper. Margin15.90%
EBITDA Margin22.17%
Profit Margin5.34%
ROE7.63%
ROA2.04%
Growth
Revenue Growth-0.90%
Earnings Growth32.90%
Cash Flow & Leverage
Operating CF1.05B $
CapEx (TTM)423.00M $
FCF Margin7.72%
FCF Yield10.52%
Net Debt8.82B $
Net Debt/EBITDA5.36
Balance Sheet
Debt/Equity1.81
Current Ratio2.37
Quick Ratio0.70
Book Value/Sh4.756 USD
Cash/Share0.3950 USD
Dividends
Fwd Div Rate0.2800 USD
Trail. Div Rate0.0000 USD
Div. Yield3.42%
5Y Avg Yield2.40%
Payout Ratio36.83%
Ex-Div DateJul 2, 2026
Pay DateJul 9, 2026
Splits
Last Split2:1
Split DateJan 4, 2016
Analyst Consensus
Rating
Target (Mean)10.87 USD
Upside (mean)+35.8%
Target Range10.00 USD11.73 USD
$10.00+35.8% to mean$11.73
# Analysts2
Ownership
Shares Out.258.22M
Float836.24M
Insiders0.00%
Institutions57.17%
Short Interest
Short Ratio4.0d
Short % Out.0.51%
Shares Short6.34M
Short (prev mo.)6.11M
Technical
SMA 507.573 (+5.6%)
SMA 2008.336 (-4.0%)
Beta1.19
S&P 52W Chg21.00%
Avg Vol (30d)217.57K
Avg Vol (10d)367.60K
Technical Indicators
RSI (14)54.8
MACD0.0970
MACD Signal0.1049
MACD Hist.-0.0079
BB Upper8.241 USD
BB Middle7.952 USD
BB Lower7.663 USD
BB Width7.27%
ATR (14)0.2227 USD
Vol Ratio (20d)0.32x